Cancer Medicine最新文献

{"title":"Tumor Regression Grade as a Predictor of Adjuvant Therapy Benefits in Esophageal Squamous Cell Carcinoma Patients After Neoadjuvant Therapy","authors":"Yizhou Huang,&nbsp;Maohui Chen,&nbsp;Yuanpu Wei,&nbsp;Bingqiang Cai,&nbsp;Yongcong Zhang,&nbsp;Chuanquan Lin,&nbsp;Shuliang Zhang,&nbsp;Taidui Zeng,&nbsp;Chun Chen,&nbsp;Bin Zheng","doi":"10.1002/cam4.71166","DOIUrl":"https://doi.org/10.1002/cam4.71166","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Neoadjuvant therapy followed by surgery is preferred for locally advanced esophageal squamous cell carcinoma (ESCC), but the necessity of adjuvant therapy remains controversial. Tumor regression grade (TRG) reflects the response to neoadjuvant therapy and may predict patient prognosis, yet its role in guiding adjuvant therapy remains unexplored. This study aimed to explore the role of TRG and other clinical characteristics in predicting the efficacy of postoperative adjuvant therapy in ESCC patients receiving neoadjuvant therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study included patients who underwent R0 esophagectomy for thoracic ESCC after neoadjuvant therapy between January 2016 and December 2021 across three high-volume centers. Patients were assessed by TRG and divided into good responders (TRG 0–1) and poor responders (TRG 2–3).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 416 patients with a median follow-up of 52 months, adjuvant therapy extended median survival by 8 months, which was statistically insignificant (<i>p</i> = 0.28). In the TRG 0–1 subgroup, those receiving adjuvant therapy had 3-year and 5-year OS rates of 94.6% and 86.8%, compared to 78.8% and 71.6% for the observation group (<i>p</i> = 0.02). Multivariable Cox regression showed adjuvant therapy was associated with reduced mortality in the TRG 0–1 (HR 0.32; 95% CI 0.14–0.73; <i>p</i> = 0.006), positive lymph nodes (HR 0.53; 95% CI 0.36–0.78; <i>p</i> = 0.001), and ypT3-4 subgroups (HR 0.63; 95% CI 0.43–0.92; <i>p</i> = 0.017).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>TRG is a promising predictor of the prognostic value of adjuvant therapy in ESCC patients. Patients with a good TRG response, positive lymph nodes, and ypT3-4 stage benefit from adjuvant therapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 18","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71166","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NIBAN2 Stimulates Glioma Growth by Regulating the JAK2/STAT3/c-Myc Pathway","authors":"Zhi-ming Chen,&nbsp;Lei Mou,&nbsp;Yi-heng Pan,&nbsp;Chi Feng,&nbsp;Jun Liu,&nbsp;Jing-jing Zhang,&nbsp;Chang-Xiang Yan","doi":"10.1002/cam4.71239","DOIUrl":"https://doi.org/10.1002/cam4.71239","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Niban-like protein 2 (NIBAN2) has recently been linked to various neurological diseases; however, its exact role in glioma development remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Quantitative reverse transcription–polymerase chain reaction, western blotting, and immunohistochemistry were used to evaluate NIBAN2 expression in glioma tissues. In addition, we examined the effects of NIBAN2 on glioma progression in various functional trials. Animal models were used to clarify the role of NIBAN2, especially its impact on the Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The research outcomes revealed that NIBAN2 was highly upregulated in gliomas and its levels were strongly correlated with tumor grade and clinical outcomes. Functional assays showed that NIBAN2 enhanced glioma cell aggressiveness by activating JAK2/STAT3 signaling and promoted tumor growth by preventing apoptosis and accelerating the cell cycle.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The findings of this study show that NIBAN2 plays a key role in glioma aggression and poor prognosis, suggesting that it is a potential therapeutic target.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 18","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71239","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioinformatics Analysis and Experimental Validation of ASF1B in Breast Tumors","authors":"Wenhao Xing,&nbsp;Meng Deng,&nbsp;Wendong Wang,&nbsp;Yueqi Liu,&nbsp;Xuefang Mi,&nbsp;Huixia Li,&nbsp;Xin Ge","doi":"10.1002/cam4.71073","DOIUrl":"https://doi.org/10.1002/cam4.71073","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To investigate the association between ASF1B expression and pathological characteristics of breast cancer, and to further explore its role in tumor progression and the immune microenvironment, thereby evaluating its potential as a therapeutic target.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>ASF1B expression in breast cancer was analyzed using the GEPIA2 and BEST databases. Its association with patient prognosis was assessed using Kaplan–Meier survival analysis. Protein co-expression networks were constructed using GeneMANIA. The correlation between ASF1B expression and immune cell infiltration was evaluated through the TIMER platform. Experimental validation was performed using qPCR and immunohistochemistry (IHC) on 67 breast cancer tissue samples.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>ASF1B expression was significantly elevated in breast cancer tissues compared to normal tissues (<i>p</i> &lt; 0.05). High ASF1B expression was associated with reduced overall and recurrence-free survival (<i>p</i> &lt; 0.05). Protein interaction analysis revealed that ASF1B was strongly linked to proteins involved in DNA replication, cell cycle progression, and chromatin remodeling. Immune analysis indicated positive correlations with B cells, neutrophils, and dendritic cells and a negative correlation with macrophage infiltration (<i>p</i> &lt; 0.05). Clinical data further showed that high ASF1B expression was significantly associated with HER2-positive breast cancer (<i>p</i> = 0.026).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>ASF1B is highly expressed in breast cancer and correlates with poor prognosis and immune cell infiltration. It may serve as a potential prognostic biomarker and therapeutic target in breast cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 18","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71073","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of the Colon Tissue Microbiome and Circulating Bile Acids With Colorectal Adenoma Among Average-Risk Women","authors":"Doratha A. Byrd,&nbsp;Maria F. Gomez,&nbsp;Stephanie R. Hogue,&nbsp;Jessica R. Burns,&nbsp;Nate Smith,&nbsp;Joshua Sampson,&nbsp;Erikka Loftfield,&nbsp;Patricia G. Wolf,&nbsp;Yunhu Wan,&nbsp;Andrew Warner,&nbsp;Belynda Hicks,&nbsp;Casey Dagnall,&nbsp;Kristine Jones,&nbsp;Youngchul Kim,&nbsp;Jin Xu,&nbsp;Jianxin Shi,&nbsp;Rashmi Sinha,&nbsp;Emily Vogtmann","doi":"10.1002/cam4.71048","DOIUrl":"https://doi.org/10.1002/cam4.71048","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The gut microbiome and bile acids (BAs) likely influence colorectal cancer (CRC) development and disparities. We conducted a nested case–control study of the associations of the colon tissue microbiome and circulating BAs with colorectal adenoma prevalence in the previously conducted multi-center Colorectal Neoplasia Screening with Colonoscopy in Average-Risk Women Regional Navy/Army Medical Centers study (CONCeRN).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We individually matched 143 women with adenoma to 279 without adenoma. Using 16S rRNA gene sequencing, we assessed alpha and beta diversity, taxonomic abundance, and co-abundance groups (CAGs). Fasting serum was analyzed for 13 primary and secondary BAs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The presence of oral-originating <i>Porphyromonas</i> was positively associated with adenomas (odds ratio [OR] and 95% confidence interval [CI] = 2.50 [1.18, 5.30]; <i>p =</i> 0.02). Race and study center explained statistically significant percentages of variation in the beta diversity matrices. BAs were generally positively associated with adenomas, though these results were not statistically significant.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>Overall, our findings suggest the colon tissue microbiome may differ by race and geography, and that certain oral-originating bacteria may be positively associated with adenomas.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 18","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71048","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Data on Inotuzumab Ozogamicin for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A GRELAL-Chile Study","authors":"Marcela Espinoza,&nbsp;Jorge Rojas-Vallejos,&nbsp;Nicolás Rodríguez,&nbsp;Gonzalo Guerrero,&nbsp;Miguel López,&nbsp;Natalia Aranguiz,&nbsp;Guillermo Conte,&nbsp;Francisco Samaniego,&nbsp;Nicolás Quinteros,&nbsp;Daniel Astete,&nbsp;Lucas Carcamo,&nbsp;Constanza Flores,&nbsp;Ximena Huerta,&nbsp;Mauricio Chandía,&nbsp;Jorge Valenzuela,&nbsp;Marcelo Navarrete,&nbsp;Yorman Flores,&nbsp;Agatha Larrazabal,&nbsp;Edgar Zapata,&nbsp;Joaquín Jerez","doi":"10.1002/cam4.71230","DOIUrl":"https://doi.org/10.1002/cam4.71230","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Inotuzumab Ozogamicin (InO) has shown efficacy in relapsed/refractory acute lymphoblastic leukemia (R/R ALL), but evidence from Latin America is scarce. We evaluated the outcomes of Chilean patients treated with InO in public and private health centers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively analyzed 35 patients with R/R ALL (median age 33 years; 54% male). Twenty percent had BCR::ABL-positive ALL, 78% expressed CD22, and 91% expressed CD19. Response rates, measurable residual disease (MRD), survival outcomes, and treatment-related toxicities were assessed. Multivariate analyses explored prognostic factors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Complete remission or remission with incomplete recovery (CR/CRi) was achieved in 74% of patients. Among those evaluated, 82% reached MRD &lt; 0.01%. Patients undergoing allogeneic hematopoietic stem cell transplantation (Allo-HSCT) after InO had superior overall survival (OS) compared with those who did not (24.2 vs. 5.2 months). Median progression-free survival (PFS) was 6.9 months and median OS was 8.8 months. Sinusoidal obstruction syndrome occurred in 14% of patients but was generally mild. Multivariate analysis identified comorbidities and high blast counts as adverse prognostic factors, whereas MRD negativity and subsequent Allo-HSCT were associated with improved outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>InO demonstrated high remission and MRD negativity rates in Chilean patients with R/R ALL, with OS and PFS comparable to existing research. Although SOS incidence was higher, it was generally mild. Achieving MRD negativity and proceeding to Allo-HSCT provided the greatest survival benefit. Study limitations include short follow-up and limited data.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 18","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71230","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Implications of Cutaneous Metastases in Colorectal Cancer: A Comprehensive Systematic Review and Meta-Analysis","authors":"Elliot Tokarski,&nbsp;Pierre-Louis Conan,&nbsp;Hugo Picchi,&nbsp;Brice Malgras,&nbsp;Evelyne Peroux,&nbsp;Anne-Cecile Ezanno","doi":"10.1002/cam4.71197","DOIUrl":"https://doi.org/10.1002/cam4.71197","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Management of cutaneous metastases in colorectal cancer is crucial because it can significantly impact patient survival.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To assess the global prognosis of skin metastases among patients treated for colorectal cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic review of the PubMed database only was conducted for English articles or reports published between 1 January 1990 and 1 November 2023. Reports concerning clinical outcomes of patients with cutaneous metastases of colorectal cancer and systematic reviews of the literature were included. Study characteristics and results of eligible studies were independently extracted by two reviewers (A.C.E., E.T.). The histology, locations, and prognosis of patients with skin metastases of colorectal cancer were analyzed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Data were obtained from almost 100 articles, most of which were case reports. Follow-up data were available for 62 patients. The most common site was rectal adenocarcinoma (58%), followed by right and left colon adenocarcinomas. A significant number of these metastases were metachronous (61%). The median time to death was 5.5 months [interquartile range, 3–10], ranging from 1 to 60 months. Treatment of cutaneous metastases, even if associated with other metastases, significantly improved overall survival (<i>p</i> &lt; 0.001; hazard ratio, 0.15), regardless of the proposed treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We carried out the most extensive review of the literature concerning cutaneous metastases of colorectal cancer to date. The review showed that cutaneous metastases are associated with a poor prognosis and short survival time. We suggest treating patients with cutaneous metastasis as if such metastasis were a surrogate marker or sentinel for aggressive metastatic disease.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 18","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71197","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers & Facilitators to Help-Seeking Behaviour for Abnormal Lower Urinary Tract Symptoms in Men: Systematic Review","authors":"Stephen McIntosh,&nbsp;Bethany Harries,&nbsp;Matthew Perry,&nbsp;Mark Cropley,&nbsp;Bridget Dibb","doi":"10.1002/cam4.71214","DOIUrl":"https://doi.org/10.1002/cam4.71214","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Men face numerous challenges when deciding whether to engage in help-seeking for abnormal lower urinary tract symptoms (LUTS), with help-seeking behaviour a multi-step process.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This systematic review explores the barriers and facilitators to help-seeking behaviour in adult men for abnormal LUTS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Eight databases (PubMed, Web of Science, Cochrane Library, EBSCOhost, SCOPUS, OVID, ProQuest and PsychINFO) were searched between January 2023 and March 2024. Studies were required to meet the inclusion criteria informed by PRISMA guidelines. Qualitative and mixed-method studies were included in the systematic review.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>(<i>N</i>) = 17 full-text articles were included in the review, totalling (<i>n</i>) = 704 participants. The systematic review uncovered four key themes: men have poor relationships with the healthcare system, some minority groups have dysfunctional cultural beliefs and attitudes towards help-seeking behaviour, traditional gender views and perceptions of masculinity discourage help-seeking behaviour and men have intrapersonal and external barriers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Men face considerable challenges when deciding to engage in help-seeking for abnormal LUTS, with men generally lacking awareness and knowledge of what they should do when experiencing symptoms. This is more profound in men from minority groups. This review may have had a language bias as non-English studies were excluded. This review may be essential to inform the development of interventions to facilitate help-seeking behaviour for abnormal LUTS in men, specifically men from minority populations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 18","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71214","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementing a Genetic Counselor-Led Model for Hereditary Myeloid Malignancies: A Real-World Study","authors":"Madeline VanDerGraaf,&nbsp;Georgianne Younger,&nbsp;Kyle Dillahunt,&nbsp;Jennifer Smith,&nbsp;Athena Puski,&nbsp;Nicole Blum,&nbsp;Hailey Manwiller,&nbsp;Jaime Nagy,&nbsp;Grerk Sutamtewagul,&nbsp;Kittika Poonsombudlert,&nbsp;Moon Ley Tung","doi":"10.1002/cam4.71240","DOIUrl":"https://doi.org/10.1002/cam4.71240","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Hereditary hematological malignancy syndromes (HHMS) are more common than previously thought, and identification of an HHMS syndrome can inform the choice of treatments, transplant, and testing of other family members. Genetic testing guidelines for hematological malignancy have broadened; however, there remain a multitude of barriers and complexities with germline genetic testing for these patients. Here, we describe a process for the evaluation and testing of patients for HHMS as well as our respective findings.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Adult patients with a new diagnosis or history of myeloid malignancy and referred for genetic counseling from 2020 to 2023 within a single institution were reviewed. Descriptive statistics were performed, and frequency data was gathered for relevant patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of forty-nine patients were evaluated by a genetic counselor based on their myeloid malignancy; forty-three patients underwent genetic testing. Genetic testing revealed an HHMS for six patients, with two additional patients found to have abnormalities on ancillary testing that could not be genetically characterized. Thirty-five patients met NCCN age-based criteria for genetic testing; however, this was not mutually exclusive with those diagnosed with HHMS. Inpatient genetic counseling had a median timeline of 53 days from referral to result (range: 32–56.75 days). Outpatient genetic counseling had a median timeline of 96 days from referral to result (range: 64–144 days).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our proposed process demonstrates an efficient structure for patients with hematological malignancy while supporting the importance of the genetic counselor within the malignant hematology and stem cell transplant teams.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 18","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71240","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145037958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Avelumab Maintenance on Advanced Urothelial Carcinoma: A Real-World Multicenter Study","authors":"Noritaka Ishii,&nbsp;Yuya Sekine,&nbsp;Masanao Shinohara,&nbsp;Yohei Kawashima,&nbsp;Kanami Mori,&nbsp;Mizuki Kobayashi,&nbsp;Kazuyuki Numakura,&nbsp;Jotaro Mikami,&nbsp;Naoki Fujita,&nbsp;Teppei Okamoto,&nbsp;Takahiro Yoneyama,&nbsp;Ryuji Tabata,&nbsp;Satoshi Sato,&nbsp;Tomonori Habuchi,&nbsp;Chikara Ohyama,&nbsp;Shingo Hatakeyama","doi":"10.1002/cam4.71241","DOIUrl":"https://doi.org/10.1002/cam4.71241","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Oncological outcomes in patients with urothelial carcinoma treated with avelumab maintenance therapy or conventional platinum-based first-line chemotherapy were compared in real-world practice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Outcomes in patients with advanced urothelial carcinoma treated with platinum-based first-line chemotherapy without avelumab (chemo group, <i>n</i> = 300) or avelumab maintenance therapy (avelumab group, <i>n</i> = 85) between March 2004 and September 2024 were retrospectively evaluated. Overall survival (OS) in the chemo and avelumab groups was stratified by the number of cycles of first-line chemotherapy. The primary outcome was OS among patients without progressive disease (non-PD) at the cycle-4 assessment (the standard-switch cohort). The secondary outcome was OS among patients with non-PD at the cycles-2 to 3 assessment (the early-switch cohort).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In the standard-switch cohort (non-PD at cycle 4), the chemo and avelumab groups comprised 122 and 47 patients, respectively; median OS was significantly longer with avelumab than with chemo (70 vs. 26 months; <i>p</i> = 0.015). In the early-switch cohort (non-PD at cycles 2–3), the chemo and avelumab groups comprised 104 and 35 patients, respectively; median OS was significantly longer with avelumab than with chemo (33 vs. 13 months; <i>p</i> = 0.002). A multivariable Cox regression analysis revealed that avelumab administration was significantly associated with a reduced risk of OS (hazard ratio, 0.37; <i>p</i> &lt; 0.001). The retrospective design is a limitation of this study.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Avelumab maintenance appeared to improve outcomes across cycles 2–3 and ≥ 4, though residual confounding cannot be excluded.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 18","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71241","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Place vs. Pocketbook: Associations of Area-Level and Individual-Level Income on Oral Cavity Cancer Late-Stage Diagnosis","authors":"Ethan Tsai,&nbsp;Brighman Walker,&nbsp;Shiao-Chi Wu","doi":"10.1002/cam4.71238","DOIUrl":"https://doi.org/10.1002/cam4.71238","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Late-stage diagnosis of oral cavity cancer (OCC) often results from diagnostic delays due to healthcare access limitations or financial barriers. This study investigates how area-level (“place”) and individual-level (“pocketbook”) income influence the stage at OCC diagnosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective cohort study analyzed data on patients diagnosed with OCC between 2010 and 2013 sourced from Taiwan's National Cancer Registry and National Health Insurance databases. The primary outcome was late-stage diagnosis, defined as those initially diagnosed at stage III or IV. Multivariable analyses were conducted to estimate the association between area-level, individual-level, and late-stage diagnosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>This study included 16,652 incident OCC patients, with 6639 (39.9%) diagnosed at a late stage and 10,013 (60.1%) at an early stage. Patients with low individual incomes residing in low-income areas had 1.48 times higher odds (95% CI = 1.09 to 2.00, <i>p</i> = 0.011) of late-stage diagnosis compared to high-income patients in high-income areas. High-income patients; however, in low-income areas had 1.34 times higher odds (95% CI = 1.05 to 1.71, <i>p</i> = 0.02) to be diagnosed at a late stage compared to high-income patients in high-income areas.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>While area-level income plays a significant role in late-stage OCC diagnosis, higher individual income does not fully protect against late-stage diagnosis in low-income areas.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 18","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71238","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}